INTERIM REPORT
2008

FIRST HALF YEAR

TECAN

Contents

About Tecan

Tecan is a leading global supplier of laboratory instruments and solutions for the biopharma, forensic and diagnostic industries. The company specializes in the development, production and distribution of automation solutions for life science laboratories. Through its REMP subsidiary, Tecan is the premier supplier of automated laboratory storage and logistics systems. Its customers include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company owns production, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries.

Vision

Tecan will be the preferred supplier for leading life science companies and laboratories on all continents, whenever they source their current and future needs for state-of-the-art workflow solutions. Tecan will be in every laboratory.

Mission

To delight our customers by exceeding their expectations, aiming for the highest customer satisfaction and retention in our industry. To contribute to the quality of life of humankind by enabling our customers to make the world and our community a healthier and safer place. To create continuous, sustainable shareholder value and to be the employer of choice in our industry.

Letter to shareholders

Dear Shareholders,

Tecan continued to display strong operational earnings power in the first half of 2008. The EBIT margin and the profit margin almost reached the high level recorded last year. A decline in both earnings before interest and taxes (EBIT) and in net profit was largely a result of unfavourable currency effects and an operating loss in the business unit Sample Management. The currency effects had a detrimental impact on Tecan's sales development in the first half of the year – in particular due to the depreciation of the US dollar against the Swiss franc. Tecan generated moderate growth in local currency. The company maintained its strong balance sheet and made further great progress in areas of strategic importance in the first six months of 2008.

Innovation is extremely important to Tecan. We introduced a variety of innovative products, applications and additions to our overall market offering in the first half of the year. These included instruments from different business segments, components such as software and modules to further improve the efficiency of the applications. We also launched various innovations in consumables. Along with instruments and software, consumables form an increasingly important component of a complete solution. Further products and applications are scheduled for introduction in the second half of the year, and are expected to make a major contribution to future sales development.

Tecan has turned the focus of the service business even more towards client needs, with a new structure under the Te-Care™ brand. Services on offer are now defined more clearly, and are available in three globally standardised versions. As of 1 July 2008, the service section of the Sample Management business segment has been integrated into Tecan's service unit, in order to offer clients a central point of contact for all areas.

We have also made great progress in strategically important cooperations. Development in the cooperation initiated around a year ago with Applied Biosystems is encouraging. We collaborate to provide the human identification area of the forensics market with a highly automated integrated system for DNA sample processing. Our offering has been well received in the market. In our collaboration with Monash University in Australia to jointly develop a fully automated production system for monoclonal antibodies, the system was put into operation. The new system is one of the largest and most state-of-the-art in the world. It now supplies international research institutions and pharmaceuticals companies with monoclonal antibodies of the high quality required, and helps to ease the existing bottlenecks in antibody production.

In order to realise its growth strategy, Tecan is fast expanding business with OEM clients. This had a positive effect on the financial figures for the first half of 2008. Several of Tecan's projects developed over the past few years are now starting to generate turnover. The company has expanded and extended business with existing clients. The pipeline of potential future projects is well stocked, which creates opportunities for long-term growth in OEM business. This encouraging development supports our strategy of further expanding OEM business with high priority.

There is also good news regarding regulatory requirements: Tecan recently passed important investigations by the US Food and Drug Administration (FDA) and the State Food and Drug Administration (SFDA) of the People's Republic of China. Meeting supervisory obligations and standards is vital for diagnostic testing and a basic requirement for our business.

Key figures first half year

CHF million	2006	2007	2008	▲07/08
Sales	200.7	196.2	183.6	-6.4%
Gross profit	94.0	99.0	92.0	-7.0%
in % of sales	46.8%	50.4%	50.1%	
R&D	19.7	20.7	18.7	-9.4%
in % of sales	9.8%	10.5%	10.2%	
OPEX	70.8	74.1	68.9	-7.0%
in % of sales	35.3%	37.7%	37.5%	
Operating profit/EBIT	23.1	24.8	23.1	-7.1%
in % of sales	11.5%	12.7%	12.6%	
Net profit	17.6	21.8	19.0	-12.7%
in % of sales	8.8%	11.1%	10.4%	
EPS (CHF)	1.54	1.89	1.71	-9.5%

Sales development marked by currency effects

Unfavourable currency developments, in particular the depreciation of the US dollar against the Swiss franc, led Tecan's sales to fall by 6.4% over the prior-year period, to CHF 183.6 million (H1 2007: CHF 196.2 million). Tecan achieved a 0.3% increase in sales in local currency.

After weak development in North America in the prior-year period, Tecan achieved sales growth of 6.2% in local currency there. Sales declined slightly in Europe. The development in the various European countries was mixed. Sales declined overall in Asia. Although they increased in the emerging Chinese market, they were significantly lower in Japan than in H1 2007. Tecan's strategically important worldwide OEM business recorded strong growth. Consumables and the service business also achieved considerable growth.

Order entry declined by 2.1% to CHF 186.9 million in the first half of the year largely as a result of currency effects (H1 2007: CHF 190.9 million). In local currency Tecan achieved order entry growth of 5.4%.

Strong profitability maintained

Tecan once again displayed strong operational earnings power with an EBIT margin of 12.6% in the first half of 2008 (H1 2007: 12.7%). At CHF 23.1 million, earnings before interest and taxes (EBIT) for the first six months of 2008 was 7.1% below that of the first half of 2007 (H1 2007: CHF 24.8 million). The decline is largely attributable to the depreciation of the US dollar against the Swiss franc and an operating loss in the business segment Sample Management. The negative currency effect on the operating profit of Tecan was CHF 5.9 million. However, higher margins and cost discipline enabled Tecan to recoup CHF 4.2 million of this, and limit the difference in the operating profit to CHF -1.7 million. The high EBIT margin generated in the largest business segment Liquid Handling & Robotics increased yet further.

As a result of the lower operating profit and a CHF 2.5 million lower financial result, Tecan's semi-annual net profit was 12.7% below the prior-year period at CHF 19.0 million (H1 2007: CHF 21.8 million). Tecan was able to maintain its strong net profit margin at 10.4% of sales (H1 2007: 11.1%). Compared to the record levels of the previous year, earnings per share of CHF 1.71 were lower (H1 2007: CHF 1.89).

Business segment information

Components & Detection

Sales in the Components & Detection business segment fell by 12.8% in H1 2008 to CHF 47.8 million (H1 2007: CHF



«Tecan continued to display strong operational earnings power in the first half of 2008.»

Mike Baronian
Chairman of the Board of Directors

Thomas Bachmann
Chief Executive Officer

54.7 million). The decline is largely due to a higher vulnerability to exchange rate fluctuations of the US dollar, an increased competitiveness of US-based peer companies as a result of the US dollar depreciation and a high basis effect driven by unusually high components sales in the first half of 2007. Sales dropped by 4.8% in local currency. Despite the decline in sales, Components & Detection slightly increased its EBIT margin to 8.7% of sales, compared with 8.6% for the same period the previous year. At CHF 4.5 million, earnings before interest and taxes (EBIT) was 12.5% lower than that of the first half of 2007 (H1 2007: CHF 5.2 million).

Liquid Handling & Robotics

Tecan's largest business segment, Liquid Handling & Robotics, demonstrated encouraging performance in the first half of 2008, generating around two-thirds of group sales. In Swiss francs, sales of CHF 122.5 million remained largely unchanged against the prior-year period. Sales in local currency increased by 7%. Liquid Handling & Robotics recorded strong sales growth, primarily in the OEM business, the sale of consumables and the service section. EBIT rose by 16% to CHF 26.9 million (H1 2007: CHF 23.1 million). The EBIT margin increased to 21.8% of sales (H1 2007: 18.7%), a level comparing favourably to international peers. This is evidence of the sustainable nature of measures designed to increase operating efficiencies implemented in the last few years. Orders in Swiss francs were considerably higher than the first half of 2007, and recorded a double-digit increase in local currency.

Sample Management

Sales in the Sample Management business segment fell in H1 2008 by 29% (27.5% in local currency) from CHF 18.8 million to CHF 13.3 million. Following EBIT of CHF 1.1 million in the prior-year period, Sample Management posted an operating loss of CHF 4.0 million for the first six months of 2008. This unsatisfactory performance was due to sustained tension in the market for large-scale storage systems, the delayed market launch of Sample Safe® and the high investments in R&D for that innovative storage system. Sample Management has introduced measures to increase sales and earnings power. These measures include strengthened marketing activities and project management and increasing efforts to lower costs. Since July 1st, 2008, the business segment has been headed by Domingo Messerli, a manager with international industry experience.

At the beginning of July, after the reporting period ended, Sample Management concluded a pending order for a large-scale plant in the amount of over 5 million Swiss francs from a leading European pharmaceuticals company. This amount is not included in the sales or order entry figures for the first half of the year.

Strong balance sheet – high equity ratio

The equity ratio rose once again to 54.7% as at 30 June 2008 (30 June 2007: 53.3%). Tecan achieved the higher equity ratio despite the buy-back of more than 350,000 of the company's own shares in the first half of 2008. Net liquidity on the reporting date was CHF 29.6 million (30 June 2007: CHF 33.3 million). Tecan's balance sheet thus remains strong. The capital reduction and the par-value repayment of CHF 0.45 per share approved at the Annual General Meeting on 23 April 2008 were undertaken on 18 July 2008. The par value of a registered share is now CHF 0.10 per share.

Outlook

We assume that the low US dollar to Swiss franc exchange rate will continue for the rest of the financial year. This will also have a negative impact on sales performance in the second half of 2008. Tecan aims to continue to implement its long-term growth strategy, thus driving on product innovation and tapping new geographic markets and customer segments. To sustain the company's high level of profitability, Tecan implements additional measures for increased efficiency and maintains strict cost discipline. If the macroeconomic challenges do not become any tougher, we believe that an increase in sales in local currency can still be achieved with no change in operating profitability over the previous year, on the basis of solid orders and a good project pipeline.

Männedorf, 13 August 2008

Mike Baronian
Chairman of the Board of Directors

Thomas Bachmann
Chief Executive Officer

Interim consolidated balance sheet

CHF 1,000	Notes	31.12.2007	30.6.2008
Assets			
Cash and cash equivalents		102,850	85,396
Derivatives		3,281	5,096
Trade accounts receivable		87,285	80,968
Other accounts receivable		12,187	12,888
Inventories		37,488	43,363
Income tax receivable		5,788	742
Prepaid expenses		2,814	5,018
Current assets		**251,693**	**233,471**
Non-current financial assets		1,674	1,732
Property, plant and equipment		22,106	20,587
Intangible assets		84,450	83,198
Deferred tax assets		14,059	12,900
Non-current assets		**122,289**	**118,417**
Assets		**373,982**	**351,888**
Liabilities and equity			
Current bank liabilities and derivatives		37,682	15,667
Trade accounts payable		9,542	9,979
Other accounts payable		11,400	10,652
Deferred revenue		20,535	22,488
Income tax payable		10,274	3,106
Accrued expenses		33,393	26,278
Current provisions		12,731	12,842
Current liabilities		**135,557**	**101,012**
Bank loans		15,246	40,253
Liability for post-employment benefits		6,465	6,352
Non-current provisions		3,089	3,053
Other non-current liabilities		609	528
Deferred tax liabilities		8,372	8,194
Non-current liabilities		**33,781**	**58,380**
Share capital		6,643	6,645
Capital reserve		14,191	14,401
Treasury shares		(41,697)	(64,338)
Retained earnings		238,455	253,040
Translation differences		(12,948)	(17,252)
Shareholders' equity	**5**	**204,644**	**192,496**
Liabilities and equity		**373,982**	**351,888**

Interim consolidated income statement

January to June, CHF 1,000	Notes	2007	2008
Sales	**7**	**196,243**	**183,638**
Cost of sales		(97,335)	(91,655)
Gross profit		**98,908**	**91,983**
Sales and marketing		(33,836)	(32,636)
Research and development		(20,683)	(18,738)
General and administration		(19'766)	(17,667)
Other operating income		208	114
Operating profit		**24,831**	**23,056**
Financial income		2,257	1,098
Finance cost		(1,079)	(533)
Foreign exchange gains/(losses)		1,260	(657)
Financial result		***2,438***	***(92)***
Profit before taxes		**27,269**	**22,964**
Income taxes		(5,454)	(3,927)
Net profit		**21,815**	**19,037**
Basic earnings per share (CHF/share)		1.89	1.71
Diluted earnings per share (CHF/share)		1.88	1.71

Interim consolidated statement of changes in shareholders' equity

January to June, CHF 1,000	Share capital	Capital reserve	Treasury shares	Retained earnings	Translation differences	Total share-holders' equity
Shareholders' equity at January 1, 2007	12,006	8,718	(16,619)	190,608	(10,872)	183,841
Net profit	-	-	-	21,815	-	21,815
Translation differences	-	-	-	-	849	849
Total recognized income and expense						***22,664***
Dividends paid	-	-	-	(5,176)	-	(5,176)
New shares issued upon exercise of employee stock options	69	3,561	-	-	-	3,630
Share-based payments to employees	-	-	-	280	-	280
Change in treasury shares (net)	-	-	(7,065)	-	-	(7,065)
Shareholders' equity at June 30, 2007	**12,075**	**12,279**	**(23,684)**	**207,527**	**(10,023)**	**198,174**
Shareholders' equity at January 1, 2008	6,643	14,191	(41,697)	238,455	(12,948)	204,644
Net profit	-	-	-	19,037	-	19,037
Translation differences	-	-	-	-	(4,304)	(4,304)
Total recognized income and expense						***14,733***
Dividends paid*)	-	-	-	(5,003)	-	(5,003)
New shares issued upon exercise of employee stock options	2	210	-	-	-	212
Share-based payments to employees	-	-	-	551	-	551
Change in treasury shares (net)	-	-	(22,641)	-	-	(22,641)
Shareholders' equity at June 30, 2008	**6,645**	**14,401**	**(64,338)**	**253,040**	**(17,252)**	**192,496**

*) 2008: CHF 0.45 per share on 11,117,437 shares with right to dividend

There were no other items of income and expense recognized directly in equity other than translation differences.

Interim consolidated cash flow statement

January to June, CHF 1,000	2007	2008
Net profit	21,815	19,037
Adjustments for:		
Depreciation and amortization	5,832	5,804
Change in provisions and liability for post-employment benefits	1,535	705
Financial result	(2,438)	92
Income taxes	5,454	3,927
Other non-cash items	946	240
Change in working capital:		
Trade accounts receivable	10,004	2,344
Inventories	(2,400)	(8,577)
Trade accounts payable	(456)	630
Other changes in working capital (net)	(16,844)	(7,071)
Income taxes paid	(8,166)	(5,955)
Cash inflows from operating activities	**15,282**	**11,176**
Interest received	1,724	1,023
Purchase of property, plant and equipment	(3,505)	(2,285)
Proceeds from sales of property, plant and equipment	-	10
Purchase of intangible assets	(877)	(590)
Cash outflows from investing activities	**(2,658)**	**(1,842)**
New shares issued upon exercise of employee stock options	3,630	212
Dividends paid	(5,176)	(5,003)
Purchase of treasury shares	(7,065)	(22,641)
Change in current bank liabilities	307	(145)
Increase in bank loans	334	341
Repayment of bank loans	(2,095)	(2,000)
Interests paid	(1,054)	(522)
Cash outflows from financing activities	**(11,119)**	**(29,758)**
Translation differences	724	(2,077)
Increase/(decrease) in cash and cash equivalents	**2,229**	**(22,501)**
Cash and cash equivalents at January 1	84,747	102,850
Cash and cash equivalents at June 30	**86,976**	**80,349**
Cash and cash equivalents as per cash flow statement comprise:		
Cash and cash equivalents as per balance sheet	97,816	85,396
./. Bank overdrafts under bank pooling arrangements	(10,840)	(5,047)
= Cash and cash equivalents as per cash flow statement	**86,976**	**80,349**

Notes to the interim consolidated financial statements

1 Introduction

These unaudited financial statements are the interim consolidated financial statements of Tecan Group Ltd., a company registered in Switzerland, and its subsidiaries (together referred to as the 'Group') for the six-month period ended June 30, 2008. The Group is a leading global supplier of laboratory instruments and solutions for the biopharma, forensic and diagnostics industries and specializes in the development, production and distribution of automation solutions for life science laboratories. Through its REMP subsidiary, the Group is the premier supplier of automated laboratory storage and logistics systems. Its customers include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company owns production, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries.

The interim consolidated financial statements were authorised for issuance on July 30, 2008.

2 Basis of preparation and accounting policies

2.1 Basis of preparation

The interim consolidated financial statements are prepared in accordance with International Accounting Standard (IAS) 34 'Interim Financial Reporting'. They should be read in conjunction with the Group's annual financial statements as they provide an update of previously reported information.

The preparation of these interim consolidated financial statements requires management to make assumptions and estimates that affect the reported amounts of revenues, expenses, assets, liabilities and disclosure of contingent liabilities at the date of these interim financial statements. If in the future such assumptions and estimates deviate from the actual circumstances, the original assumptions and estimates will be modified as appropriate in the period in which the circumstances change.

Income tax expense is recognized based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated average annual tax rate used for 2008 is 17.1% (the estimated tax rate used for the first six months of 2007 was 20.0%).

The Group operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the financial year.

2.2 Introduction of new and amended accounting standards and interpretations

The accounting policies used in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the year ended December 31, 2007, except for the adoption of the following new interpretations, effective as from January 1, 2008: IFRIC 11, 12 and 14.

The adoption of these changes did not result in substantial changes to the Group's accounting policies.

2.3 New standards and interpretations not yet applied

The following new and revised standards and interpretations have been issued, but are not yet effective and are not applied early in these consolidated financial statements:

Standard / interpretation*)	Effective date for the Group
IFRS 2 amended 'Share-based Payment – Vesting Conditions and Cancellations'	January 1, 2009
IFRS 8 'Operating Segments'	January 1, 2009
IAS 1 revised 'Presentation of Financial Statements'	January 1, 2009
IAS 23 revised 'Borrowing Costs'	January 1, 2009
IAS 32 amended 'Financial Instruments: Presentation' and IAS 1 amended 'Presentation of Financial Statements' – Puttable Financial Instruments and Obligations Arising on Liquidation	January 1, 2009
Improvements to IFRSs	January 1, 2009
IFRIC 13 'Customer Loyality Programmes'	January 1, 2009
IFRS 3 revised 'Business Combination' and IAS 27 amended 'Consolidated and Separate Financial Statements'	January 1, 2010

*) IAS = International Accounting Standard, IFRS = International Financial Reporting Standard, IFRIC = International Financial Reporting Interpretations Committee

IFRS 8 'Operating Segments' might change segment disclosures. All other changes are not expected to have a significant impact on the consolidated financial statements.

3 Change in scope of consolidation (acquisitions)

There were no changes in the scope of consolidation during 2007 and 2008.

4 Principal exchange rates

		Balance sheet (Closing exchange rates)		Income statement (Average exchange rates January to June)	
CHF		31.12.2007	30.6.2008	2007	2008
EUR	1	1.65	1.60	1.63	1.60
USD	1	1.13	1.02	1.23	1.04

5 Shareholders' equity and employee stock options

5.1 Reduction of nominal value

The annual general meeting of shareholders approved on April 23, 2008 a total payout of CHF 0.90 per share for 2007, which comprises a regular dividend of CHF 0.45 and a payout of CHF 0.45 per share in form of a reduction of the nominal value of each share from CHF 0.55 to CHF 0.1. This payout was completed in July 2008.

5.2 Movements in shares outstanding

Number (each share has a nominal value of CHF 0.55)	Shares issued	Treasury shares	Shares outstanding
Balance at January 1, 2007	12,005,607	(461,730)	11,543,877
Issue of new shares from conditional share capital (employee participation plan)	69,167	-	69,167
Purchase of treasury shares	-	(81,333)	(81,333)
Balance at June 30, 2007	**12,074,774**	**(543,063)**	**11,531,711**
Balance at January 1, 2008	12,078,381	(772,900)	11,305,481
Issue of new shares from conditional share capital (employee participation plan)	4,210	-	4,210
Purchase of treasury shares	-	(353,010)	(353,010)
Balance at June 30, 2008	**12,082,591**	**(1,125,910)**	**10,956,681**

The Group completed a share buyback program on the first trading line on the SWX Swiss Exchange on May 13, 2008. This program was initiated on January 9, 2007. During the course of the program a total 627,287 shares were repurchased.
As approved by the shareholders at the annual general meeting on April 23, 2008, the Group has started a new share buyback program on a second trading line on the SWX Swiss Exchange on May 16, 2008. These shares will be cancelled and the share capital reduced accordingly. The program is limited to a maximum of 10% of the share capital.

5.3 Authorized share capital

The shareholders agreed to a two-year extension of the approval for the authorized capital created in 2006 and its increase from 10% to 20% of the share capital.

Number (each share has a nominal value of CHF 0.55)	31.12.2007	30.6.2008
Authorised share capital, expiring on April 26, 2008	1,200,000	-
Authorised share capital, expiring on April 23, 2010	-	2,400,000

5.4 Employee stock options

The number of outstanding employee stock options at the end of June was 282,858 options (June 30, 2007: 221,313 options). 4,210 options have been exercised during the first six months of 2008, which resulted in a share capital increase of CHF 0.0 million and a cash inflow of CHF 0.2 million (first six months of 2007: 69,167 options, which resulted in a share capital increase of CHF 0.1 million and a cash inflow of CHF 3.6 million).

6 Contingent liabilities

No significant changes.

7 Interim segment information

7.1 Segment information by business segments

	Components & Detection		Liquid Handling & Robotics		Sample Management		Corporate / consolidation		Group	
CHF 1,000	2007	2008	2007	2008	2007	2008	2007	2008	2007	2008
Sales to third parties	54,745	47,757	122,694	122,535	18,804	13,346	-	-	196,243	183,638
Intersegment sales	5,055	4,273	1,339	646	825	549	(7,219)	(5,468)	-	-
Total sales	**59,800**	**52,030**	**124,033**	**123,181**	**19,629**	**13,895**	**(7,219)**	**(5,468)**	**196,243**	**183,638**
Operating profit	**5,159**	**4,512**	**23,142**	**26,861**	**1,131**	**(4,017)**	**(4,601)**	**(4,300)**	**24,831**	**23,056**
Depreciation and amortization	(1,917)	(1,519)	(2,568)	(2,688)	(1,347)	(1,597)	-	-	(5,832)	(5,804)
Impairment losses	-	-	-	-	-	-	-	-	-	-
Purchase of property, plant and equipment	1,685	687	1,480	1,504	340	94	-	-	3,505	2,285
Purchase of intangible assets	339	227	538	330	-	33	-	-	877	590
	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008
Segment assets	46,286	42,407	117,573	119,681	77,629	77,227	-	-	241,488	239,315
Unallocated assets									132,494	112,573
Total assets									**373,982**	**351,888**
Segment liabilities	18,615	15,736	45,402	45,113	14,459	13,047	-	-	78,476	73,896
Unallocated liabilities									90,862	85,496
Total liabilities									**169,338**	**159,392**

Intersegment transactions are conducted at arm's length. No significant non-cash expenses other than depreciation of property, plant and equipment and amortization of intangible assets were incurred.

7.2 Sales by regions (by location of customers)

	North America		Europe		Asia		Others		Total	
CHF 1,000	2007	2008	2007	2008	2007	2008	2007	2008	2007	2008
Sales to third parties	74,161	68,131	90,409	85,185	26,835	21,299	4,838	9,023	196,243	183,638

7.3 Segment information by location of assets

	Europe		America		Asia		Corporate / consolidation		Group	
CHF 1,000	2007	2008	2007	2008	2007	2008	2007	2008	2007	2008
Purchase of property, plant and equipment	2,875	1,877	617	388	13	20	-	-	3,505	2,285
Purchase of intangible assets	877	590	-	-	-	-	-	-	877	590
	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008	31.12. 2007	30.06. 2008
Segment assets	234,222	235,756	62,461	55,897	10,674	9,994	(60,397)	(54,934)	246,960	246,713
Unallocated assets									127,022	105,175
Total assets									**373,982**	**351,888**

8 Operating expenses by nature

January to June, CHF 1,000	2007	2008
Material costs	61,226	53,830
Personnel expenses	68,148	64,129
Depreciation of property, plant and equipment	3,246	4,019
Amortization of intangible assets	2,586	1,785
Other operating income and expenses (net)	36,206	36,819
Total operating expenses	**171,412**	**160,582**

9 Subsequent events

No events have occurred subsequent to the balance sheet date, which would require adjustments to or disclosures in these interim consolidated financial statements.

Publisher
Tecan Group Ltd.
Seestrasse 103
CH-8708 Männedorf
Martin Braendle
Head of Corporate Communications &
Investor Relations
Phone: +41 44 922 84 30
Fax: +41 44 922 88 89
investor@tecan.com
www.tecan.com

This Interim Report is available in English and German and can also be found at the website www.tecan.com. The English report is the authoritative version.

Tecan Group

Seestrasse 103, CH-8708 Männedorf, Switzerland
www.tecan.com
–